tetano
Editor, Senior Moderator
Front Immunol. 2018 Jul 30;9:1705. doi: 10.3389/fimmu.2018.01705. eCollection 2018.
[h=1]Enhanced Immune Responses Conferring Cross-Protection by Skin Vaccination With a Tri-Component Influenza Vaccine Using a Microneedle Patch.[/h] Zhu W[SUP]1[/SUP], Li S[SUP]2[/SUP], Wang C[SUP]1[/SUP], Yu G[SUP]3[/SUP], Prausnitz MR[SUP]2[/SUP], Wang BZ[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Skin vaccination using biodegradable microneedle patch (MNP) technology in vaccine delivery is a promising strategy showing significant advantages over conventional flu shots. In this study, we developed an MNP encapsulating a 4M2e-tFliC fusion protein and two types of whole inactivated influenza virus vaccines (H1N1 and H3N2) as a universal vaccine candidate. We demonstrated that mice receiving this tri-component influenza vaccine via MNP acquired improved IgG1 antibody responses with more balanced IgG1/IgG2a antibody responses and enhanced cellular immune responses, including increased populations of IL-4 and IFN-γ producing cells and higher frequencies of antigen-specific plasma cells compared with intramuscular injection. In addition, stronger germinal center reactions, increased numbers of Langerin-positive migratory dendritic cells, and increased cytokine secretion were observed in the skin-draining lymph nodes after immunization with the tri-component influenza MNP vaccine. The MNP-immunized group also possessed enhanced protection against a heterologous reassortant A/Shanghai/2013 H7N9 (rSH) influenza virus infection. Furthermore, the sera collected from 4M2e-tFliC MNP-immunized mice were demonstrated to have antiviral efficacy against reassortant A/Vietnam/1203/2004 H5N1 (rVet) and A/Shanghai/2013 H7N9 (rSH) virus challenges. The immunological advantages of skin vaccination with this tri-component MNP vaccine could offer a promising approach to develop an easily applicable and broadly protective universal influenza vaccine.
[h=4]KEYWORDS:[/h] H7N9 influenza virus; immune responses; influenza vaccine; microneedle patch; skin vaccination
PMID: 30105019 PMCID: PMC6077188 DOI: 10.3389/fimmu.2018.01705
Free PMC Article
[h=1]Enhanced Immune Responses Conferring Cross-Protection by Skin Vaccination With a Tri-Component Influenza Vaccine Using a Microneedle Patch.[/h] Zhu W[SUP]1[/SUP], Li S[SUP]2[/SUP], Wang C[SUP]1[/SUP], Yu G[SUP]3[/SUP], Prausnitz MR[SUP]2[/SUP], Wang BZ[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Skin vaccination using biodegradable microneedle patch (MNP) technology in vaccine delivery is a promising strategy showing significant advantages over conventional flu shots. In this study, we developed an MNP encapsulating a 4M2e-tFliC fusion protein and two types of whole inactivated influenza virus vaccines (H1N1 and H3N2) as a universal vaccine candidate. We demonstrated that mice receiving this tri-component influenza vaccine via MNP acquired improved IgG1 antibody responses with more balanced IgG1/IgG2a antibody responses and enhanced cellular immune responses, including increased populations of IL-4 and IFN-γ producing cells and higher frequencies of antigen-specific plasma cells compared with intramuscular injection. In addition, stronger germinal center reactions, increased numbers of Langerin-positive migratory dendritic cells, and increased cytokine secretion were observed in the skin-draining lymph nodes after immunization with the tri-component influenza MNP vaccine. The MNP-immunized group also possessed enhanced protection against a heterologous reassortant A/Shanghai/2013 H7N9 (rSH) influenza virus infection. Furthermore, the sera collected from 4M2e-tFliC MNP-immunized mice were demonstrated to have antiviral efficacy against reassortant A/Vietnam/1203/2004 H5N1 (rVet) and A/Shanghai/2013 H7N9 (rSH) virus challenges. The immunological advantages of skin vaccination with this tri-component MNP vaccine could offer a promising approach to develop an easily applicable and broadly protective universal influenza vaccine.
[h=4]KEYWORDS:[/h] H7N9 influenza virus; immune responses; influenza vaccine; microneedle patch; skin vaccination
PMID: 30105019 PMCID: PMC6077188 DOI: 10.3389/fimmu.2018.01705
Free PMC Article